1. Home
  2. CNXC vs IMCR Comparison

CNXC vs IMCR Comparison

Compare CNXC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

N/A

Current Price

$29.47

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$26.33

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNXC
IMCR
Founded
1991
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.5B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
CNXC
IMCR
Price
$29.47
$26.33
Analyst Decision
Buy
Buy
Analyst Count
5
12
Target Price
$32.60
★ $59.30
AVG Volume (30 Days)
★ 802.8K
414.0K
Earning Date
09-29-2026
11-06-2026
Dividend Yield
★ 5.18%
N/A
EPS Growth
N/A
★ 30.39
EPS
N/A
★ N/A
Revenue
★ $9,825,771,000.00
$249,428,000.00
Revenue This Year
$0.26
$9.28
Revenue Next Year
N/A
$9.91
P/E Ratio
N/A
★ N/A
Revenue Growth
2.15
★ 43.05
52 Week Low
$19.12
$26.53
52 Week High
$44.78
$40.71

Technical Indicators

Market Signals
Indicator
CNXC
IMCR
Relative Strength Index (RSI) 46.02 32.57
Support Level $28.51 N/A
Resistance Level $30.75 $31.75
Average True Range (ATR) 1.90 1.46
MACD -0.41 -0.46
Stochastic Oscillator 17.10 9.12

Price Performance

Historical Comparison
CNXC
IMCR

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: